The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them
an invaluable cell type for the repair of tissue/organ damage caused by chronic inflammation …

Mesenchymal stem cell therapy (MSCT) for immune and inflammatory diseases continues to
be popular based on progressive accumulation of preclinical mechanistic evidence. This …

The advancement of microRNA (miRNA) therapies has been hampered by difficulties in
delivering miRNA to the injured kidney in a robust and sustainable manner. Using …

Mesenchymal stem cells form a population of self‐renewing, multipotent cells that can be
isolated from several tissues. Multiple preclinical studies have demonstrated that the …

Lifelong immunosuppressive therapy is essential to prevent allograft rejection in transplant
recipients. Long-term, nonspecific immunosuppression can, however, result in life …

Mesenchymal stromal cells (MSCs) are the subject of numerous clinical trials, largely due to
their immunomodulatory and tissue regenerative properties. Toll-like receptors (TLRs) …

Background Aging frailty, characterized by decreased physical and immunological
functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem …

The prevalence of kidney diseases is emerging as a public health problem. Stem cells
(SCs), currently considered as a promising tool for therapeutic application, have aroused …

Bone marrow-derived mesenchymal stem cells (MSC) have unique immunomodulatory and
reparative properties beneficial for allotransplantation cellular therapy. The clinical …

The ultimate goal in transplantation medicine is the promotion of operational tolerance.
Although Th cells of the Th17 type have been predominantly associated with rejection of …